Jessica Pan 0:03
My name is Jessica Pan and today I'm here to represent Radiance Therapeutics. Joining Radiance was not just a career move for me, it's a personal crusade. We're here to change the narrative for glaucoma, and lighting our page ensuring that glaucoma patients are met with the light and hope of innovation. Glaucoma is the leading cause of irreversible blindness worldwide. It is an irreversible disease with no cure. The cause is thought to be of high intraocular pressure in your eye, which causes damage to the optic nerve. And then which causes blindness. It's a silent thief with no early symptoms. 50% of patients don't even know they have glaucoma. And the current treatment is to reduce IOP to arrest the progression, so it is a disease with significant unmet need. 48 point 2 million patients are diagnosed worldwide 1.1 3 million will have the surgery, including 432,000. That is a specific type of drainage surgery which I will address later. And over 120,000 patients in the US are blinded from glaucoma. This means it costs our healthcare system significant economic burden. It's 5.8 billion in direct costs and 2.9 billion and indirect costs. The current standard of care exhibits high failure rates, which we are hoping to address. So to talk a little bit more about drainage surgery, so this intervention is for our moderate to severe glaucoma patients. And the complications are very high. Three years we see that about 50% of these patients fail due to scarring which is what we're addressing. And there are two types of drainage surgery. The first is called a Tribeca colectomy. This is a traditional type of surgery, it's using a Scalpel to make an incision in the eye to alleviate that pressure. And the second type is a newer type of surgery called MCs, which stands for Transscleral minimally invasive glaucoma surgery. So rather than using a Scalpel, what you use as a stent or shunt into the eye to do the same thing of alleviating that pressure in your eye. So what is our sole solution? Our moonshot technology is a radiate is a beta therapy device. It's a Breakey therapy source and specifically provides a certain type of radiation called strontium 90. It's a topical application. It's quick, it's only 30 seconds. And it's easy to use, intuitive and non invasive. So we are unique for our size, because there's already four randomized control trials that have already been published on our technology. And now I'll go through two of them specifically. The first one is comparing us to just placebo. So this is a Kaplan Meier survival curve. It's by Kieran at all and 300 and patients, the red line is our placebo line, and the blue is our beta radiation. And so what we see here is that at three years postdoc 50% of our patients fail the placebo, and whereas in the red line 10%, failed beta, and all of the patients between these two lines are at risk of going blind. And then how about beta radiation compared to the current standard of care, which is a drug called Mito Meissen. See, it is also an oncology drug. It comes in liquid form, and it's painted on your eye. In this also randomized control trial, we see that we are 3.2 times more likely to have a functioning drainage reservoir compared to MMC treated eyes. And we're 5.6 times more likely to have a lower IOP. So what does all of this data tell us beta therapy is the better better therapy. And this is also proven by randomized control trials, which is the gold standard of in the hierarchy of evidence. And what's our target market? So this is data that was from market scope, which is a premier industry analysis. And what they see here is for the Mitel myosin see surgeries, the estimated amount in 2023 is 479,000. And in five years, this is projected to grow to 727,000. And so with a conservative reimbursement amount, we see that today the market is 500 million more than 500 million, and it's projected to grow Up to 750 million and we will achieve this through a razor razor blade business model. And what's our moat so we have our intellectual property our patents are already issued we have 10 that are pending. We are already 510 K cleared we received our 510 K last year. And we have our supply chain and manufacturing already in place with a fortune 200 and our partner will be dropped shipping these directly to the hospitals. This is an area of very active m&a with large upfront payments. All of our success is on the shoulders of RKO wells. We have Dr. Ike Ahmed from University of Toronto Dr. Singh from Stanford and serpin call and Keith bar in for more fields I hospital. To summarize, why should you invest in radiants? We're solving the leading cause of blindness. We have world renowned specialists that are part of our team. We're replacing the standard of care with Mido Meissen. See and this is evidence based through the four RCTs that are already published in primary journals. We have our 510 K clearance and our core patents issued. I look forward to speaking many of you thank you
© 2024 Life Science Intelligence, Inc., All Rights Reserved.
